Moderna (NASDAQ:MRNA) PT Lowered to $115.00 at Piper Sandler

Moderna (NASDAQ:MRNA) had its price target decreased by Piper Sandler from $157.00 to $115.00 in a research note released on Friday morning, Benzinga reports. Piper Sandler currently has an overweight rating on the stock.

Several other equities research analysts have also weighed in on the company. Hsbc Global Res raised Moderna from a moderate sell rating to a hold rating in a research report on Wednesday, August 28th. Barclays cut their price objective on shares of Moderna from $168.00 to $155.00 and set an overweight rating on the stock in a research report on Friday, August 2nd. HSBC raised shares of Moderna from a reduce rating to a hold rating and set a $82.00 target price for the company in a research note on Wednesday, August 28th. Jefferies Financial Group lowered shares of Moderna from a buy rating to a hold rating and dropped their price target for the company from $120.00 to $65.00 in a research note on Friday. Finally, Oppenheimer downgraded Moderna from an outperform rating to a market perform rating in a research report on Friday. One analyst has rated the stock with a sell rating, thirteen have given a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of Hold and an average price target of $103.93.

Moderna Price Performance

Shares of NASDAQ:MRNA opened at $69.17 on Friday. The company has a quick ratio of 3.92, a current ratio of 4.09 and a debt-to-equity ratio of 0.05. The firm has a 50-day simple moving average of $94.12 and a 200 day simple moving average of $111.72. Moderna has a fifty-two week low of $62.55 and a fifty-two week high of $170.47. The company has a market cap of $26.51 billion, a PE ratio of -4.41 and a beta of 1.67.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, beating the consensus estimate of ($3.47) by $0.14. The company had revenue of $241.00 million during the quarter, compared to analyst estimates of $128.41 million. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The business’s revenue was down 29.9% compared to the same quarter last year. During the same period in the prior year, the company earned ($3.62) earnings per share. On average, sell-side analysts anticipate that Moderna will post -9.52 EPS for the current year.

Insider Transactions at Moderna

In related news, CFO James M. Mock sold 689 shares of the stock in a transaction that occurred on Monday, July 8th. The shares were sold at an average price of $118.24, for a total transaction of $81,467.36. Following the completion of the sale, the chief financial officer now directly owns 7,269 shares of the company’s stock, valued at $859,486.56. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Moderna news, CFO James M. Mock sold 689 shares of the company’s stock in a transaction on Monday, July 8th. The stock was sold at an average price of $118.24, for a total value of $81,467.36. Following the transaction, the chief financial officer now owns 7,269 shares of the company’s stock, valued at $859,486.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO James M. Mock sold 1,321 shares of the firm’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the sale, the chief financial officer now directly owns 8,600 shares of the company’s stock, valued at $682,754. The disclosure for this sale can be found here. Insiders have sold 93,158 shares of company stock valued at $11,167,312 in the last quarter. Insiders own 15.70% of the company’s stock.

Institutional Trading of Moderna

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Quadrant Capital Group LLC raised its holdings in shares of Moderna by 7.5% during the fourth quarter. Quadrant Capital Group LLC now owns 2,672 shares of the company’s stock valued at $266,000 after acquiring an additional 187 shares during the period. Ontario Teachers Pension Plan Board acquired a new stake in Moderna during the 4th quarter valued at $1,358,000. Hobbs Group Advisors LLC purchased a new stake in shares of Moderna in the fourth quarter valued at $664,000. Illinois Municipal Retirement Fund boosted its position in shares of Moderna by 22.1% in the first quarter. Illinois Municipal Retirement Fund now owns 51,791 shares of the company’s stock worth $5,519,000 after buying an additional 9,360 shares during the period. Finally, Swedbank AB purchased a new position in shares of Moderna during the first quarter valued at $3,315,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.